J

Author

James Okoro

Regulation & Policy Correspondent

James Okoro has covered financial regulation and market policy for 9 years, reporting on rulemaking from securities regulators and the compliance obligations facing banks and brokerages. He holds a law degree with a focus on financial services regulation and worked as a compliance associate at a regional bank before moving into journalism. His analysis breaks down new rules and enforcement actions for a general audience.

Covers:
  • regulation
  • analysis
Latest by James Okoro
Biotech Firm Scribe Therapeutics Files for US Initial Public Offering

Biotech Firm Scribe Therapeutics Files for US Initial Public Offering

Jul 12, 2026

Scribe Therapeutics, a biotechnology company, has submitted a registration statement for an initial public offering on the Nasdaq Global Market. The company plans to trade under the ticker 'SCTX' but has not yet detailed the number of shares or price range for the offering.

Holtec Nuclear Corporation Files for US Initial Public Offering

Holtec Nuclear Corporation Files for US Initial Public Offering

Jul 12, 2026

Energy company Holtec Nuclear Corporation has filed for an initial public offering in the U.S., aiming to fund the development of its small modular reactor technology. The firm plans to list on Nasdaq and Nasdaq Texas under the ticker 'HNUC'.